U.S. Justice Department Subpoenas Health Records of Young Transgender Patients
29 Percent of Infants Immunized Against RSV in 2023 to 2024 Season
Infant RSV immunization coverage through nirsevimab or maternal vaccination ranged from an estimated 11 to 53 percent by state
FDA Suspends U.S. License of Chikungunya Vaccine
Ixchiq has been linked to more than 20 serious adverse events resembling chikungunya illness
FDA Approves Papzimeos for Adults With Recurrent Respiratory Papillomatosis
Papzimeos is the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis
Weather Disasters Impacted Counties With More Than 60 Percent of Drug Production Facilities
All types of climate-related disasters were declared in at least one county with an active drug production facility, with hurricanes most common
FDA Clears OTC Glucose Monitoring System for Weight Management
System integrates glucose biosensor with an AI-driven platform to show how food, activity, stress, sleep affect the body in real time
Use of Vaginal Estradiol Tablets Not Linked to Recurrent Stroke
Exposure to vaginal estradiol not linked to increased rate of recurrent ischemic stroke when adjusted for comorbidity, medications, income, education
OTC Oral Contraceptive Pills Improve Access to Effective Contraception
OTC access linked to 31.8 percentage point increase in individuals moving from no contraceptive method to an effective method
FDA Approves Papzimeos for Adults With Recurrent Respiratory Papillomatosis
Papzimeos is the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis
TAR-200 Monotherapy Promising for BCG-Unresponsive Bladder Cancer
TAR-200 monotherapy was well tolerated, with high complete response rate and prolonged disease-free survival
